Imunon chair receives stock grant instead of salary

Tardugno Michael H reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Tardugno Michael H reported acquisition or exercise transactions in this Form 4 filing.

Imunon, Inc. executive chairman Michael H. Tardugno reported a compensation-related stock grant rather than an open-market trade. He received 4,629 shares of Common Stock at $1.82 per share, granted in lieu of cash for base salary, bringing his direct holdings to 17,467 shares. A separate line shows 4,622 shares of Common Stock held indirectly through an IRA, reflecting existing indirect ownership rather than a new market transaction.

Insights

Equity compensation analyst

Routine equity compensation grant replaces part of cash salary.

The filing shows Imunon’s executive chairman receiving 4,629 shares of Common Stock at $1.82 per share as a grant or award. A footnote states this stock was granted in lieu of cash for base salary, indicating a compensation choice rather than a market trade.

Because the transaction uses code A and is classified as a grant/award acquisition, it reflects standard equity-based pay. After the grant, direct ownership rises to 17,467 shares, while an additional 4,622 shares are held indirectly in an IRA. No derivative exercises or sales appear in this filing.

Insider Trade Summary

Grant/Award: 4,629 shares

Grant/Award 2 txns

Insider Tardugno Michael H

Role Executive Chairman of Board

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	4,629	$1.82	$8K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 17,467 shares (Direct); Common Stock — 4,622 shares (Indirect, Held by IRA)

Footnotes (1)

1. F1. Stock granted in lieu of cash for base salary

Key Figures

Stock grant shares: 4,629 shares Grant price: $1.82 per share Direct holdings after grant: 17,467 shares +1 more

4 metrics

Stock grant shares 4,629 shares Common Stock grant in lieu of cash base salary

Grant price $1.82 per share Value used for the 4,629-share award

Direct holdings after grant 17,467 shares Common Stock directly owned after acquisition

Indirect IRA holdings 4,622 shares Common Stock held indirectly via IRA

Key Terms

Grant, award, or other acquisition, Held by IRA, Common Stock, base salary

4 terms

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Held by IRA financial

"nature_of_ownership: Held by IRA"

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

base salary financial

"Stock granted in lieu of cash for base salary"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Imunon (IMNN) report for Michael H. Tardugno?

Imunon reported that executive chairman Michael H. Tardugno received a grant of 4,629 shares of Common Stock. The shares were awarded at $1.82 per share as part of his compensation, rather than purchased or sold in the open market.

Was the Imunon (IMNN) Form 4 transaction a stock purchase or sale?

The Form 4 does not show an open-market purchase or sale. Instead, it records a grant or award acquisition of 4,629 Imunon Common Stock shares at $1.82 per share, given in lieu of cash for base salary according to the footnote.

How many Imunon (IMNN) shares does Michael H. Tardugno hold after this filing?

After the reported grant, Michael H. Tardugno directly holds 17,467 shares of Imunon Common Stock. The filing also shows an additional 4,622 shares held indirectly through an IRA account, reflecting his indirect beneficial ownership position.

What does the $1.82 price on the Imunon (IMNN) Form 4 represent?

The $1.82 figure is the per-share value used for the 4,629-share stock grant. It represents the price applied to this compensation award, which was granted in lieu of cash salary, rather than a price from an open-market trade.

How is the Imunon (IMNN) executive’s IRA reported in this Form 4?

The Form 4 lists 4,622 Imunon Common Stock shares as held indirectly by an IRA. This entry is categorized as indirect beneficial ownership, showing shares currently in the IRA rather than a new acquisition or sale on the transaction date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 07:59 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tardugno Michael H

(Last) (First) (Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE NEW JERSEY 08648

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Chairman of Board

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2026		A		4,629(1)	A	$1.82	17,467	D
Common Stock								4,622	I	Held by IRA

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Stock granted in lieu of cash for base salary

	/s/ Susan Eylward, Attorney-in-Fact for Michael Tardugno	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)